While Provenge targets PAP, improved efficacy may be found with another promising target for prostate tumor immunotherapy, prostate-specific antigen (PSA), a protein widely expressed in prostate adenocarcinomas (Cunha et al., 2006). The gene discussed is KLK3; the disease is prostate neoplasm.